Coronary stenting has a high rate of failure, with 10-40% of patients developing restenosis within 6 months. Activation of the complement system and subsequent inflammation play a pivotal role in this process. The aim of this work was to develop a biomimetic stent coating that inhibits complement activation and prevents restenosis. A two part coating was developed using End Group Activated Pluronic (EGAP) in conjunction with factor H, a potent complement regulator. EGAP was applied to pretreated, stainless steel and nitinol stents and factor H was subsequently coupled through activation sites on EGAP. Coatings were characterized by ELISA for factor H. The coating reduced complement activation in human serum as measured by assays for C3a and surface bound complement convertase. The coating was also nonthrombogenic as measured by reduced platelet adhesion and low thrombin anti-thrombin levels. This approach should prove useful for reducing restenosis associated with stenting.